Latest Partnerships News

Atomo Diagnostics reports a significant expansion in its supply agreement with Lumos for the Pascal test cassette, tied to the promising CLIA waiver status of the FebriDx test in the US. This deal could nearly double Atomo’s revenues over the next three years.

Orbital Corporation reveals a strategic pivot amid evolving US drone policies, with a new management team driving growth beyond Boeing Insitu. FY25 guidance shows revenue decline but promising new contracts.

Objective Corporation reports robust FY2025 results with strong recurring revenue growth and deepening AI integration, setting ambitious targets for FY2026.

RooLife Group Ltd (ASX, RLG) has launched its proprietary RLG Coffee brand in China, tapping into a rapidly expanding market with early sales exceeding $110,000 in the first month. Strategic partnerships and a recent supply deal position RLG for broader growth in the country’s evolving consumer landscape.

Beonic Ltd has raised a total of $4.18 million through convertible notes to fund product innovation, repay debt, and advance its North African Airport Project. Major shareholders and directors are backing the raise, subject to shareholder approval.

Papyrus Australia clarifies it has signed a binding term sheet, not a final agreement, with AQN for biodegradable boards, contingent on facility setup and product testing.

Vanadium Resources Limited is progressing towards Direct Shipping Ore operations at Steelpoortdrift, advancing key conditions for a binding offtake agreement with China Precious Asia Limited while optimizing mining readiness and exploring growth opportunities.

BPH Global Ltd reports a robust 50.9% increase in seaweed sales for July 2025, driven by strong domestic demand in Indonesia and plans to expand internationally.

NRW Holdings delivered a robust FY25 performance, posting a 12.2% revenue increase to $3.27 billion and securing a strong $6.1 billion order book. The company’s FY26 outlook remains positive with expected revenue growth and improved earnings.

Tinybeans Group Ltd reported a significant reduction in losses and a 12% rise in subscription revenue for FY25, driven by a strategic pivot away from advertising. The company’s restructuring efforts have improved cash flow and positioned it for sustainable growth.

Tryptamine Therapeutics has secured an exclusive agreement with leading neuroscientists to develop a novel EEG-based brain entropy biomarker aimed at enhancing precision psychiatry for its psychedelic drug TRP-8803.

Medical Developments International Ltd reported an 18% increase in revenue to $39.1 million for FY25, returning to profitability with a net profit after tax of $0.1 million. The company advanced its Penthrox market expansion through regulatory approvals and new partnerships.